Biomerieux, Inc.

Hospices Civils De Lyon

Institut Pasteur

Ecole Nationale Veterinaire D'alfort

L'assistance Publique - Hopitaux De Paris

Pathoquest

Pathquest

Assistance Publique-hopitaux De Paris

Philippe Perot

François Mallet

Nathalie Mugnier

Marc Eloit

Jean Deregnaucourt

Nicolas Torno

Marion Mouton

Isabelle Heard

Jérémy Becker

Cécile Montgiraud

The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.

Broad range gene and genotype papillomavirus transcriptome as a biomarker of papillomavirus-associated cancer stages

The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of lung cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, a method for use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences.

Method for the diagnosis or prognosis, in vitro, of lung cancer

The subject matter of the present invention is a method for the diagnosis or prognosis, in vitro, of testicular cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, which have been isolated, as a molecular marker or molecular markers, and a kit including at least one binding partner specific for at least one of the expression products of the HERV nucleic acid sequences.

Method for the diagnosis or prognosis, in vitro, of testicular cancer

The present invention relates to a method for the in vitro diagnosis or prognosis of prostate cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit comprising at least one specific binding partner of at least one of the expression products of the HERV nucleic acid sequences.

Method for the diagnosis or prognosis, in vitro, of prostate cancer

The present invention relates to a method for in vitro diagnosis or prognosis of colon cancer, including a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said isolated nucleic acid sequences as a molecular marker/molecular markers, and a kit including at least one specific binding partner for at least one expression product of the HERV nucleic acid sequences.

Method for in vitro diagnosis or prognosis of colon cancer

The present invention relates to a method for the in vitro diagnosis or prognosis of ovarian cancer, which includes a step of detecting at least one expression product of at least one HERV nucleic acid sequence, the use of said nucleic acid sequences, once isolated, as one or more molecular marker(s) and a kit including at least one specific binding partner of at least one of the expression products of the HERV nucleic acid sequences.

Method for the in vitro diagnosis or prognosis of ovarian cancer

A method for estimating the affinity &#x3d5; of a first DNA strand, or 'probe', to be hybridized with a second DNA strand, or 'target', to form a hybrid of length L, the method comprising: in each division of a set of M divisions of the hybrid, counting the number of times in which each hybrid of a set of P DNA strand hybrids is present in the division, the hybrids being of length k less than the length L, or &#x201c;k-hybrids&#x201d;; for each combination of mismatches of a set of L combinations of mismatches in a hybrid of length Lbp, determining whether the pair of mismatches is present in the hybrid; and calculating the affinity &#x3d5; according to the relation: 

Growing community of inventors

Lyons, France

Philippe Perot